David W. Hillman

Benign Breast Disease and the Risk of Breast Cancer

Lynn C. Hartmann, Thomas A. Sellers, Marlene H. Frost et al. · New England Journal of Medicine · 2005 · 929 citations · Full text

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart, Eileen Holmes, José Baselga et al. · Journal of Clinical Oncology · 2015 · 370 citations · Full text

The Body in Parts: Fantasies of Corporeality in Early Modern Europe

Mary Thomas Crane, David W. Hillman, Carla Mazzio · Shakespeare Quarterly · 1999 · 280 citations

Literary Theory, New York, Comparative Literature +17

Folate receptor overexpression is associated with poor outcome in breast cancer

Lynn C. Hartmann, Gary L. Keeney, Wilma L. Lingle et al. · International Journal of Cancer · 2007 · 243 citations · Full text

<i>HER2</i> and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Edith A. Perez, Monica M. Reinholz, David W. Hillman et al. · Journal of Clinical Oncology · 2010 · 231 citations · Full text